DEC-C Post-Transplant
A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 126 patients (estimated)
- Sponsors
- Washington University School of Medicine
- Collaborators
- Taiho Oncology, Inc.
- Tags
- Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Minimal Residual Disease (MRD), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1513
- NCT Identifier
- NCT04742634
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.